Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Chelle

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Research and Practice in Thrombosis and Haemostasis|November 11, 2021
External qualification of the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) models for octocog alfa using real patient dataPierre Chelle, Dagmar Hajducek, Mohammed Mahdi, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 20, 2019
Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualizationAlanna McEneny-King, Pierre Chelle, Gary Foster, et al.
Journal of Clinical Pharmacology|June 29, 2021
Pediatric Dose Selection for Therapeutic ProteinsPaul R V Malik, Zaid H Temrikar, Pierre Chelle, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 3, 2024
Development of a Plasminogen Population PK model supporting prophylactic replacement therapy for Plasminogen deficient patients within the WAPPS-Hemo platformPierre Chelle, Dagmar Hajducek, Karen Thibaudeau, et al.
Pharmaceutics|October 18, 2017
Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A ProphylaxisAlanna McEneny-King, Pierre Chelle, Severine Henrard, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 14, 2020
Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo projectDagmar M Hajducek, Pierre Chelle, Cedric Hermans, et al.
Hemasphere|March 31, 2022
Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe HemophiliaOlav Versloot, Emma Iserman, Pierre Chelle, et al.
Journal of Thrombosis and Haemostasis : JTH|May 20, 2021
Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS databaseOlav Versloot, Emma Iserman, Pierre Chelle, et al.
Nanoscale|January 27, 2018
A method for the quantitative extraction of gold nanoparticles from human bronchoalveolar lavage fluids through a glycerol gradientDimitrios Bitounis, Vincent Barnier, Cyril Guibert, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 29, 2019
Tissue factor pathway inhibitor is the main determinant of thrombin generation in haemophilic patientsPierre Chelle, Aurélie Montmartin, Pauline Damien, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Research and Practice in Thrombosis and Haemostasis|November 11, 2021
External qualification of the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) models for octocog alfa using real patient dataPierre Chelle, Dagmar Hajducek, Mohammed Mahdi, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 20, 2019
Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualizationAlanna McEneny-King, Pierre Chelle, Gary Foster, et al.
Journal of Clinical Pharmacology|June 29, 2021
Pediatric Dose Selection for Therapeutic ProteinsPaul R V Malik, Zaid H Temrikar, Pierre Chelle, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 3, 2024
Development of a Plasminogen Population PK model supporting prophylactic replacement therapy for Plasminogen deficient patients within the WAPPS-Hemo platformPierre Chelle, Dagmar Hajducek, Karen Thibaudeau, et al.
Pharmaceutics|October 18, 2017
Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A ProphylaxisAlanna McEneny-King, Pierre Chelle, Severine Henrard, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 14, 2020
Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo projectDagmar M Hajducek, Pierre Chelle, Cedric Hermans, et al.
Hemasphere|March 31, 2022
Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe HemophiliaOlav Versloot, Emma Iserman, Pierre Chelle, et al.
Journal of Thrombosis and Haemostasis : JTH|May 20, 2021
Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS databaseOlav Versloot, Emma Iserman, Pierre Chelle, et al.
Nanoscale|January 27, 2018
A method for the quantitative extraction of gold nanoparticles from human bronchoalveolar lavage fluids through a glycerol gradientDimitrios Bitounis, Vincent Barnier, Cyril Guibert, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 29, 2019
Tissue factor pathway inhibitor is the main determinant of thrombin generation in haemophilic patientsPierre Chelle, Aurélie Montmartin, Pauline Damien, et al.
Pageof 4